View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
View PDF Version - RePub - Erasmus Universiteit Rotterdam
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Chapter 2.2<br />
58<br />
26. Bonino F, Lau GKK, Marcellin P, Hadziyannis S, Kitis G, Jin R, Yao GB, Piratvisuth T, Germanidis<br />
G, Yurdaydin C, Diago M, Gurel S, Lai MY, McCloud P, Brunetto MR, Farci P. The<br />
fi rst detailed analysis of predictors of response in HBeAg-negative chronic hepatitis B:<br />
data from a multicenter, randomized, partially double-blind study of peginterferon-alfa-2a<br />
(4-KD) (Pegasys®) alone or in combination with lamivudine vs lamivudine alone. Hepatology<br />
2004;40:A1142.<br />
27. European Association For The Study Of The L. EASL Clinical Practice Guidelines: management<br />
of chronic hepatitis B. J Hepatol 2009;50:227-42.<br />
28. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. Development of a quantitative<br />
real-time detection assay for hepatitis B virus DNA and comparison with two commercial<br />
assays. J Clin Microbiol 2000;38:2897-901.<br />
29. Steyerberg EW, Eijkemans MJ, Harrell FE, Jr., Habbema JD. Prognostic modelling with logistic<br />
regression analysis: a comparison of selection and estimation methods in small data<br />
sets. Stat Med 2000;19:1059-79.<br />
30. Steyerberg EW, Harrell FE, Jr., Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal<br />
validation of predictive models: effi ciency of some procedures for logistic regression<br />
analysis. J Clin Epidemiol 2001;54:774-81.<br />
31. Harrell FE. Regression Modeling Strategies with Applications to Linear Models, Logistic<br />
Regression, and Survival Analysis. Springer-Verlag New York, LLC, 2006.<br />
32. de Franchis R, Hadengue A, Lau G, Lavanchy D, Lok A, McIntyre N, Mele A, Paumgartner G,<br />
Pietrangelo A, Rodes J, Rosenberg W, Valla D. EASL International Consensus Conference<br />
on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long<br />
version). J Hepatol 2003;39:S3-25.<br />
33. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-<br />
Pacifi c consensus statement on the management of chronic hepatitis B: a 2008 update.<br />
Hepatol Int 2008:DOI 10.1007/s12072-008-9080-3.<br />
34. Zoulim F, Perrillo R. Hepatitis B: refl ections on the current approach to antiviral therapy. J<br />
Hepatol 2008;48 Suppl 1:S2-19.<br />
35. Craxi A, Di Bona D, Camma C. Interferon-alpha for HBeAg-positive chronic hepatitis B. J<br />
Hepatol 2003;39 Suppl 1:S99-105.<br />
36. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw<br />
YF, Button P, Popescu M. HBeAg and hepatitis B virus DNA as outcome predictors during<br />
therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology<br />
2008;47:428-34.<br />
37. Buster EH, Hansen BE, Zeuzem S, Schalm SW, Steyerberg EW, Janssen HL. Predicting sustained<br />
HBeAg loss after treatment with peginterferon alpha-2b: development and validation<br />
of a practical model. Hepatology 2007;46:684A-685A.<br />
38. Grandjacques C, Pradat P, Stuyver L, Chevallier M, Chevallier P, Pichoud C, Maisonnas M,<br />
Trepo C, Zoulim F. Rapid detection of genotypes and mutations in the pre-core promoter